Boosting Pediatric Cancer Drug Research, Organ Transplant Efficiency, and Generic Drug Access.
This Act mandates pharmaceutical companies to study new adult cancer drugs for pediatric use if the drug targets relevant molecular pathways, aiming to increase treatment options for children with cancer. It also significantly reforms the organ transplantation system (OPTN) by promoting digitalization and transparency. Furthermore, the law facilitates the market entry of cheaper generic drugs and allocates additional funds to the Medicare Improvement Fund.
Key points
Faster Pediatric Cancer Treatments: Drug companies must investigate new targeted cancer drugs for potential use in children, speeding up access to specialized therapies.
Organ Transplant Transparency: The organ transplant network (OPTN) must integrate electronic health records and increase public transparency regarding organ utilization.
Status:
Passed House
Record your position for audit.
Why does your vote on bills matter?
It creates raw, undeniable proof. Civic Will provides the permanent data to verify the Government's loyalty towards its citizens
(explained here).
Start recording it now.